Tuesday, 15 June 2021, 08:00 HKT/SGT

Source: Eisai

TOKYO, June 15, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma.

Zonegran is an antiepileptic drug (AED) originally created by Dainippon Pharmaceutical Co., Ltd. (currently Sumitomo Dainippon Pharma Co., Ltd.), for which Eisai holds the exclusive rights in a number of European countries, the Middle East, Russia, Australia, Canada, Mexico, and Asian countries. Under this agreement, Eisai will divest its rights associated with Zonegran in such European countries, the Middle East, Russia, and Australia to Advanz Pharma. Eisai will continue to act as the distributor in Russia, through its local affiliate Limited Liability Company Eisai, and Australia through its local affiliate Eisai Australia Pty. Ltd., for an agreed transition period. In addition, Eisai and Advanz Pharma have agreed to enter into a supply agreement under which Eisai's UK affiliate, Eisai Manufacturing Ltd., will serve as Advanz Pharma's supplier of Zonegran for the transferred territory for an agreed transition period.

Eisai will retain its rights to Zonegran in Canada, Mexico and Asian countries and continue to distribute the product in certain licensed Asian countries.

Eisai believes that this divestiture agreement with Advanz Pharma will lead to maximization of the antiepileptic agent's product value. In addition, the agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families.

Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network

Eisai

Dec 23, 2024 16:22 HKT/SGT

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

Dec 11, 2024 13:45 HKT/SGT

Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia

Dec 5, 2024 10:22 HKT/SGT

"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

Nov 28, 2024 15:26 HKT/SGT

LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Nov 26, 2024 14:50 HKT/SGT

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan

Nov 20, 2024 10:51 HKT/SGT

Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan

Nov 20, 2024 09:24 HKT/SGT

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements

Nov 15, 2024 16:33 HKT/SGT

Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)

Nov 15, 2024 13:31 HKT/SGT

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

Nov 5, 2024 10:35 HKT/SGT

Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"

More news >>

News Alerts


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Privacy Policy \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575

Connect With us: